Oxford & AstraZeneca COVID-19 vaccine trials halted for safety review

One of the most promising COVID-19 vaccine trials has been halted; after one of its U.K participants developed a “potentially unexplained illness”. The vaccine was developed by the University of Oxford in partnership with AstraZeneca, and is currently being trialled in South Africa, Brazil, the UK and the US. Shabir Madhi, Professor of Vaccinology at the University of Witwatersrand joins CNBC Africa for more.

Partner Content

Absa commits to growing African trade with award-winning online platform

Absa launched its online trade finance portal, Trade Management Online, in 2019

Responsible banking in a post-COVID commodity market – Investing responsibly throughout the commodity value chain

While the alcohol sector invariably draws strong feelings from across the philosophical divide during Covid-19, what is indisputable...

A Cyber Pandemic May Be Next: How secure are you in the cloud?

The Coronavirus pandemic has influenced us in a more global way than the Cold War, affecting the environment, industry, finance, healthcare, leisure...

Subscribe to our newsletter

Sign up for free newsletters and get more CNBC AFRICA delivered to your inbox